BCAB Share Price Performance
US$0
-20.21 (-100.00%)
Price US$0
Fair ValueUS$8.33
Share Pricen/a
BioAtla, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
BCAB Community Narratives
AN
Fair Value
·Fair Value US$8.33 53.6% undervalued intrinsic discount
Mec-V And ROR2-ADC Programs Will Achieve Clinical Milestones
1users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Mec-V And ROR2-ADC Programs Will Achieve Clinical Milestones
Key Takeaways Promising results in clinical programs and strategic partnerships indicate potential for increased revenue, improved net margins, and financial stability through collaboration income. Resource realignment and reduced R&D expenses suggest better operational efficiency and net margin improvement over the next year.Read more
AN
US$8.33
53.6% undervalued intrinsic discount
Fair Value
Profit Margin
14.12%
Future PE
972.31x
Price in 2028
US$6.98
Trending Discussion
Recently Updated Narratives
AN
Mec-V And ROR2-ADC Programs Will Achieve Clinical Milestones
Fair Value: US$8.33 53.6% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioAtla, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -30.55
- -2,053.65%
- -2,530.85%
- 0%
About BCAB
- Founded
- 2007
- Employees
- 41
- CEO
- WebsiteView website
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
